Immunocompromised Therapies

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2351" ]
    }, {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350" ]
    }, {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2349" ]
    } ]
  },
  "date" : "2022-03-03T18:46:01-05:00",
  "meta" : {
    "versionId" : "13",
    "lastUpdated" : "2022-03-02T18:03:58.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "Lantana EH Steward",
  "jurisdiction" : [ {
    "extension" : [ {
      "valueString" : "UNKNOWN",
      "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason"
    } ]
  } ],
  "purpose" : "(Clinical Focus: This set of values contains procedures for patients who have had  immunocompromising therapies.),(Data Element Scope: The intent of this data element is to identify patients who have had immunocompromising therapies. Using the Quality Data Model, this particular element will map to the Procedure  category.),(Inclusion Criteria: Include codes representing  immunocompromised therapies including systemic chemotherapy, radiation, corticosteroid and other immunosuppressive therapies using  the  ICD 9 CM, ICD 10 PCS, and SNOMED CT  code systems.),(Exclusion Criteria: None.)",
  "name" : "ImmunocompromisedTherapies",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://hl7.org/fhir/sid/icd-9-cm",
      "code" : "00.10",
      "display" : "Implantation of chemotherapeutic agent",
      "version" : "2013"
    }, {
      "system" : "http://hl7.org/fhir/sid/icd-9-cm",
      "code" : "00.15",
      "display" : "High-dose infusion interleukin-2 [IL-2]",
      "version" : "2013"
    }, {
      "system" : "http://hl7.org/fhir/sid/icd-9-cm",
      "code" : "17.70",
      "display" : "Intravenous infusion of clofarabine",
      "version" : "2013"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "367336001",
      "display" : "Chemotherapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230301"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E00X05",
      "display" : "Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E00X0M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E01305",
      "display" : "Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0130M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E02305",
      "display" : "Introduction of Other Antineoplastic into Muscle, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0230M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E03002",
      "display" : "Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E03003",
      "display" : "Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E03005",
      "display" : "Introduction of Other Antineoplastic into Peripheral Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0300M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0300P",
      "display" : "Introduction of Clofarabine into Peripheral Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E03302",
      "display" : "Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E03303",
      "display" : "Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E03305",
      "display" : "Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0330M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0330P",
      "display" : "Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E04002",
      "display" : "Introduction of High-dose Interleukin-2 into Central Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E04003",
      "display" : "Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E04005",
      "display" : "Introduction of Other Antineoplastic into Central Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0400M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0400P",
      "display" : "Introduction of Clofarabine into Central Vein, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E04302",
      "display" : "Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E04303",
      "display" : "Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E04305",
      "display" : "Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0430M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0430P",
      "display" : "Introduction of Clofarabine into Central Vein, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E05002",
      "display" : "Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E05003",
      "display" : "Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E05005",
      "display" : "Introduction of Other Antineoplastic into Peripheral Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0500M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0500P",
      "display" : "Introduction of Clofarabine into Peripheral Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E05302",
      "display" : "Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E05303",
      "display" : "Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E05305",
      "display" : "Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0530M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0530P",
      "display" : "Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E06002",
      "display" : "Introduction of High-dose Interleukin-2 into Central Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E06003",
      "display" : "Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E06005",
      "display" : "Introduction of Other Antineoplastic into Central Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0600M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0600P",
      "display" : "Introduction of Clofarabine into Central Artery, Open Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E06302",
      "display" : "Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E06303",
      "display" : "Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E06305",
      "display" : "Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0630M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0630P",
      "display" : "Introduction of Clofarabine into Central Artery, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E09305",
      "display" : "Introduction of Other Antineoplastic into Nose, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0930M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E09705",
      "display" : "Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0970M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E09X05",
      "display" : "Introduction of Other Antineoplastic into Nose, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E09X0M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0A305",
      "display" : "Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0A30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0B305",
      "display" : "Introduction of Other Antineoplastic into Ear, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0B30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0B705",
      "display" : "Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0B70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0BX05",
      "display" : "Introduction of Other Antineoplastic into Ear, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0BX0M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0C305",
      "display" : "Introduction of Other Antineoplastic into Eye, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0C30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0C705",
      "display" : "Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0C70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0CX05",
      "display" : "Introduction of Other Antineoplastic into Eye, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0CX0M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0D305",
      "display" : "Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0D30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0D705",
      "display" : "Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0D70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0DX05",
      "display" : "Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0DX0M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0E305",
      "display" : "Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0E30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0E705",
      "display" : "Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0E70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0E805",
      "display" : "Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0E80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0F305",
      "display" : "Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0F30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0F705",
      "display" : "Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0F70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0F805",
      "display" : "Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0F80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0G305",
      "display" : "Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0G30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0G705",
      "display" : "Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0G70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0G805",
      "display" : "Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0G80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0H305",
      "display" : "Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0H30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0H705",
      "display" : "Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0H70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0H805",
      "display" : "Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0H80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0J305",
      "display" : "Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0J30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0J705",
      "display" : "Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0J70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0J805",
      "display" : "Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0J80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0K305",
      "display" : "Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0K30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0K705",
      "display" : "Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0K70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0K805",
      "display" : "Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0K80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0L305",
      "display" : "Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0L30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0L705",
      "display" : "Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0L70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0M305",
      "display" : "Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0M30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0M705",
      "display" : "Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0M70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0N305",
      "display" : "Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0N30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0N705",
      "display" : "Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0N70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0N805",
      "display" : "Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0N80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0P305",
      "display" : "Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0P30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0P705",
      "display" : "Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0P70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0P805",
      "display" : "Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0P80M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Q305",
      "display" : "Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Q30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Q705",
      "display" : "Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Q70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0R302",
      "display" : "Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0R303",
      "display" : "Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0R305",
      "display" : "Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0R30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0S302",
      "display" : "Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0S303",
      "display" : "Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0S305",
      "display" : "Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0S30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0U305",
      "display" : "Introduction of Other Antineoplastic into Joints, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0U30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0V305",
      "display" : "Introduction of Other Antineoplastic into Bones, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0V30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0W305",
      "display" : "Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0W30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Y305",
      "display" : "Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Y30M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Y705",
      "display" : "Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "3E0Y70M",
      "display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening",
      "version" : "2023"
    }, {
      "system" : "http://hl7.org/fhir/sid/icd-9-cm",
      "code" : "99.25",
      "display" : "Injection or infusion of cancer chemotherapeutic substance",
      "version" : "2013"
    }, {
      "system" : "http://hl7.org/fhir/sid/icd-9-cm",
      "code" : "99.28",
      "display" : "Injection or infusion of biological response modifier [BRM] as an antineoplastic agent",
      "version" : "2013"
    } ],
    "offset" : 0,
    "total" : 156,
    "identifier" : "urn:uuid:1258d4cc-3648-404e-af48-354f9a7f2a07",
    "timestamp" : "2023-06-29T17:57:40-04:00",
    "parameter" : [ {
      "name" : "count",
      "valueInteger" : 1000
    }, {
      "name" : "offset",
      "valueInteger" : 0
    } ]
  },
  "title" : "Immunocompromised Therapies",
  "extension" : [ {
    "valueString" : "Lantana EH Author",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2022-12-15",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2016-03-31",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "3318332a-31ed-4dbe-bf00-1d4902a776bc",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2348",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.666.5.2348"
  } ],
  "version" : "20160331"
}